Ocugen, Inc.

NASDAQ:OCGN

Biotechnology

Healthcare
$0.76 +2.46%

+$0.03 today

Market cap
$256.75M
Beta
2.21
P/E (TTM)
-5.6
EPS (TTM)
-$0.22
52W Low $0.90High $2.73

Volume 5.47M

Average 7.51M

Returns on capital

Ocugen, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

557.7%

avg 149.5%

ROIC

-278.6%

avg -112.4%

ROA

-155.9%

avg -97.8%

Analysis

ROE is currently the strongest return metric at 557.7% versus its period average of 149.5%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Shankar Musunuri

Co-Founder, Chief Executive Officer & ChairmanUSD 1.26M621.03M0.30%

Arun Upadhyay

Chief Scientific Officer and Head of Research & DevelopmentUSD 703.75K44306.20K0.09%

Mohamed Genead

Chief Medical OfficerUSD 644.03K———

Vijay Tammara

Chief Development OfficerUSD 490.92K660<0.01%

Kristen Craft

Head of People & Culture————

Rita Johnson-Greene

CFO & Principal Accounting Officer—49——

Chris Clark

VP of Corporate Communications————

Paul Staid

Executive Vice President of Operations————

Jyothy Pillai

Vice President & Head of Regulatory & Quality————

John Kouch

General Counsel————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 9, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

1

$25,830.00

Sells

4

$1.09M

Net Transaction Value

−$1.06M

Net selling

Most Active

Musunuri Shankar

4 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Oct 9, 26

Musunuri Shankar

Direct

Sell$445.3K
Oct 9, 26

Musunuri Shankar

Indirect

Sell$54.4K
Sep 9, 26

Musunuri Shankar

Direct

Sell$525K
Sep 9, 26

Musunuri Shankar

Indirect

Sell$64.1K
Jun 15, 26

Johnson-Greene Treerita Essalima

Direct

Buy$25.8K

Summary

Insiders reported 1 buys worth $25,830.00 and 4 sells worth $1.09M over the last 12 months. That adds up to net selling of $1.06M. Musunuri Shankar was the most active insider with 4 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A+21.0%
+203.3% (5yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Recent growth has been strongest in Revenue at +21.0% over three years. Forward estimates point to Revenue at +203.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Ocugen, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about OCGN's management, answered from reported figures.

Who manages OCGN?

Ocugen, Inc. (OCGN) lists 10 active executives. The top listed executive is Kristen Craft, Head of People & Culture.

Are OCGN insiders buying or selling?

Recent insider activity shows net buying of $6.62M.